Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Revision of Guidelines Beneficial for Assessing Orthostatic Hypotension

By LabMedica International staff writers
Posted on 07 Aug 2017
Researchers have found that measuring blood pressure to test for the presence of orthostatic hypotension (OH; a form of low blood pressure) should be performed within one minute of standing after a person has been lying down, instead of three minutes after.

“Our findings suggest that a blood pressure assessment within the first minute is a better way to assess health risks due to OH and that waiting three minutes might miss at-risk status,” said paper first-author Stephen Juraschek, MD, PhD, of Johns Hopkins University School of Medicine (Baltimore, MD, USA).

OH (sometimes called postural hypotension) is common among older adults, marked by dizziness, lightheadedness, and even fainting when they stand up. More...
Although sometimes related to medication side effects, anemia, or dehydration, OH in many cases has unknown causes. It may increase risk of falls and strokes, both of which can be lethal.

Clinically, a person is diagnosed with OH when systolic blood pressure drops by at least 20 mmHg during transition from lying down to standing up, or when diastolic blood pressure drops by at least 10mmHg within three minutes after standing. While a healthy person’s blood pressure will return to their baseline readings almost immediately after such a test, blood pressure for people with OH will linger at lower values for a while.

The current three-minute threshold was implemented after a review of studies and a consensus statement from the American Academy of Neurology in the late 1990s. This statement was later reiterated in 2011. In practice, however, clinicians often do not wait the recommended 3 minutes to measure blood pressure due to time constraints.

To learn whether waiting or not waiting for the three-minute threshold made any significant difference in risk assessment, Dr. Juraschek and his team analyzed blood pressure data already gathered on over 15,000 people ages 45-64 during the Atherosclerosis Risk in Communities Study (ARIC; conducted during 1987-1989). They focused on data taken from 11,429 participants who had at least 4 measurements testing for OH over time, and looked for links between measurement times and adverse events – falls, fractures, fainting, and car crashes. They also looked for association between time of measurement and death. Of the participants, 54% were women and 26% were black, with an average age of 54 years. Nearly 10% of participants self-reported a history of dizziness upon standing.

The researchers found that measurements taken within 30 seconds of standing were associated with the highest rates per 1,000 person-years of fracture (18.9), fainting (17.0), and death (31.4). Measurements taken within 1 minute were associated with the highest rate of falls (13.2 per 1,000 person-years) and car crashes (2.5). Measurements taken within 30 seconds were associated with the greatest proportion, 13.5%, of self-reported dizziness.

The findings support the idea that OH assessments performed within one minute of standing are most strongly related to self-reported dizziness and individual adverse outcomes: “If someone comes into the clinic with dizziness, we try to assess his/her risk of falling or other consequences of dizziness in the future,” said Dr. Juraschek, “These results show that assessing OH within the first minute not only is OK, but also makes a lot of sense because it’s more predictive of future falls.”

Current treatments for chronic OH include physical therapy to improve balance, lifestyle changes including drinking more fluid and eating smaller meals, altering the environment (such as using grip bars), coaching patients how to safely stand up, and changing or stopping certain medications.

The study, by Juraschek S et al, was published July 24, 2017, in the journal JAMA Internal Medicine.

Related Links:
Johns Hopkins University School of Medicine


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.